The Immunometabolic Architecture of Cardiovascular Disease: From Molecular Mechanisms to Precision Therapeutic Strategies

Authors

  • Uzma Manzoor Department of Clinical Biochemistry, COMSATS University Islamabad, Sahiwal Campus, Sahiwal, Pakistan Author
  • Omneya Abdelkarem Department of Chemical Pathology, Medical Research Institute, Alexandria University, Alexandria, Egypt Author
  • Azraida Hajar Department of Biology, Laboratory of Pharmacology, Neurobiology, Anthropobiology and Environment, Faculty of Sciences Semlalia, Cadi Ayyad University, Marrakesh-Safi, Morocco Author

DOI:

https://doi.org/10.64229/z36aqk64

Keywords:

Immunometabolic cardiovascular disease, Meta-inflammation mitochondrial dysfunction, SGLT2 inhibitors, Senolytics, Clonal hematopoiesis of indeterminate potential, Clonal genomic profiling

Abstract

Cardiovascular diseases (CVDs) remain the leading cause of global mortality, yet traditional hemodynamic and lipid-centric models prove insufficient to capture the biological complexity driving residual cardiovascular risk. Converging evidence increasingly reframes CVD pathophysiology as a systemic immunometabolic disorder driven by the interplay of mitochondrial dysfunction, chronic immune activation, clonal hematopoiesis of indeterminate potential, and metabolic stress. This review critically synthesizes emerging paradigms in precision cardiovascular medicine, spanning molecular bioenergetics, epigenetic reprogramming, and immune-metabolic crosstalk within a unified immunometabolic-precision medicine framework, and evaluates translational advances including Sodium-glucose cotransporter-2 inhibitors, senolytics, and AI-driven risk stratification that directly target these mechanisms. Looking beyond current limitations, it appraises the transformative potential of multi-omics integration and regenerative engineering as the next frontier of cardiovascular precision medicine. By translating immunometabolic mechanisms into actionable clinical frameworks, this review argues for a paradigm shift: from reactive disease management toward precision-guided, biologically informed, and equitably accessible cardiovascular care.

References

[1]Global Burden of Cardiovascular Diseases and Risks 2023 Collaborators. Global, regional, and national burden of cardiovascular diseases and risk factors in 204 countries and territories, 1990-2023. Journal of the American College of Cardiology, 2025, 86(22), 2167-2243. DOI: 10.1016/j.jacc.2025.08.015

[2]World Health Organization: WHO. Cardiovascular diseases (CVDs), 2025. Available at: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) (accessed on 31 July 2025).

[3]Aikawa M, Sonawane AR, Chelvanambi S, Asano T, Halu A, Matamalas JT, et al. Precision cardiovascular medicine: Shifting the innovation paradigm. Frontiers in Science, 2025, 3, 1474469. DOI: 10.3389/fsci.2025.1474469

[4]Lopez EO, Ballard BD, Jan A. Cardiovascular disease statpearls NCBI bookshelf. National Library of Medicine, 2023.

[5]Pietrangelo D, Lopa C, Litterio M, Cotugno M, Rubattu S, Lombardi A. Metabolic disturbances involved in cardiovascular diseases: The role of mitochondrial dysfunction, altered bioenergetics and oxidative stress. International Journal of Molecular Sciences, 2025, 26(14), 6791. DOI: 10.3390/ijms26146791

[6]Pavlović N, Todorović P, Maglica M, Kumrić M, Vukojević K, Pogorelić Z, et al. Mitochondrial dysfunction in cardiomyopathy and heart failure: From energetic collapse to therapeutic opportunity. Biomolecules, 2025, 15(11), 1572. DOI: 10.3390/biom15111572

[7]Shah MS, Brownlee M. Molecular and cellular mechanisms of cardiovascular disorders in diabetes. Circulation Research, 2016, 118(11), 1808-1829. DOI: 10.1161/CIRCRESAHA.116.306923

[8]Zeng X, Yang Y. Molecular mechanisms underlying vascular remodeling in hypertension. Reviews in Cardiovascular Medicine, 2024, 25(2), 72. DOI: 10.31083/j.rcm2502072

[9]Blaustein JR, Quisel MJ, Hamburg NM, Wittkopp S. Environmental impacts on cardiovascular health and biology: An overview. Circulation Research, 2024, 134(9), 1048-1060. DOI: 10.1161/CIRCRESAHA.123.323613

[10]Młynarska E, Bojdo K, Frankenstein H, Krawiranda K, Kustosik N, Lisińska W, et al. Endothelial dysfunction as the common pathway linking obesity, hypertension and atherosclerosis. International Journal of Molecular Sciences, 2025, 26(20), 10096. DOI: 10.3390/ijms262010096

[11]Libby P, Soehnlein O. Inflammation in atherosclerosis: Lessons and therapeutic implications. Immunity, 2025, 58(10), 2383-2401. DOI: 10.1016/j.immuni.2025.09.012

[12]YYang HM. Mitochondrial dysfunction in cardiovascular diseases. International Journal of Molecular Sciences, 2025, 26(5), 1917. DOI: 10.3390/ijms26051917

[13]Liu H, Wang S, Wang J, Guo X, Song Y, Fu K, et al. Energy metabolism in health and diseases. Signal Transduction and Targeted Therapy, 2025, 10(1), 69. DOI: 10.1038/s41392-025-02141-x

[14]Salnikova D, Orekhova V, Grechko A, Starodubova A, Bezsonov E, Popkova T, et al. Mitochondrial dysfunction in vascular wall cells and its role in atherosclerosis. International Journal of Molecular Sciences, 2021, 22(16), 8990. DOI: 10.3390/ijms22168990

[15]Zong Y, Li H, Liao P, Chen L, Pan Y, Zheng Y, et al. Mitochondrial dysfunction: Mechanisms and advances in therapy. Signal Transduction and Targeted Therapy, 2024, 9(1), 124. DOI: 10.1038/s41392-024-01839-8

[16]Cobo I, Tanaka T, Glass CK, Yeang C. Clonal hematopoiesis driven by DNMT3A and TET2 mutations: Role in monocyte and macrophage biology and atherosclerotic cardiovascular disease. Current Opinion in Hematology, 2022, 29(1), 1-7. DOI: 10.1097/MOH.0000000000000688

[17]Liu S, Anderson PJ, Rajagopal S, Lefkowitz RJ, Rockman HA. G protein-coupled receptors: A century of research and discovery. Circulation Research, 2024, 135(1), 174-197. DOI: 10.1161/CIRCRESAHA.124.323067

[18]Nordestgaard LT, Wolford BN, de Gonzalo-Calvo D, Sopić M, Devaux Y, Matic L, et al. Multiomics in atherosclerotic cardiovascular disease. Atherosclerosis, 2025, 408, 120414. DOI: 10.1016/j.atherosclerosis.2025.120414

[19]Țapoș GF, Cîmpeanu IA, Predescu IA, Liga S, Păcurar AT, Vlad D, et al. An integrative review of the cardiovascular disease spectrum: Integrating multi-omics and artificial intelligence for precision cardiology. Diseases, 2026, 14(1), 31. DOI: 10.3390/diseases14010031

[20]Mullins VA, Bresette W, Johnstone L, Hallmark B, Chilton FH. Genomics in personalized nutrition: Can you "Eat for your genes"? Nutrients, 2020, 12(10), 3118. DOI: 10.3390/nu12103118

[21]Kiani AK, Bonetti G, Donato K, Kaftalli J, Herbst KL, Stuppia L, et al. Polymorphisms, diet and nutrigenomics. Journal of Preventive Medicine and Hygiene, 2022, 63(2S3), E125-E141. DOI: 10.15167/2421-4248/jpmh2022.63.2S3.2754

[22]Grigoriou K, Karakasis P, Nasoufidou A, Stachteas P, Klisic A, Karagiannidis E, et al. SGLT2 inhibitors in the management of cardio-renal-metabolic syndrome: A new therapeutic era. Medicina, 2025, 61(11), 1903. DOI: 10.3390/medicina61111903

[23]Bodapati AP, Hanif A, Okafor DK, Katyal G, Kaur G, Ashraf H, et al. PCSK-9 inhibitors and cardiovascular outcomes: A systematic review with meta-analysis. Cureus, 2023, 15(10), e46605. DOI: 10.7759/cureus.46605

[24]Papadakis Z. Exercise in CKM syndrome progression: A stage-specific approach to cardiovascular, metabolic, and renal health. Cardiovascular Diabetology, 2025, 24(1), 462. DOI: 10.1186/s12933-025-03029-4

[25]Frąk W, Wojtasińska A, Lisińska W, Młynarska E, Franczyk B, Rysz J. Pathophysiology of cardiovascular diseases: New insights into molecular mechanisms of atherosclerosis, arterial Hypertension, and coronary artery disease. Biomedicines, 2022, 10(8), 1938. DOI: 10.3390/biomedicines10081938

[26]Nevoit G, Potyazhenko M, Mintser O, Jarusevicius G, Vainoras A. Mitochondrial dysfunction in the cardiovascular disease continuum: Problems of studying the progression during the follow-up of the pathologies. International Journal of Molecular Sciences, 2025, 26(21), 10497. DOI: 10.3390/ijms262110497

[27]Józkowiak M, Niebora J, Domagała D, Data K, Partyńska A, Kulus M, et al. New insights into endothelial cell physiology and pathophysiology. Biomedicine & Pharmacotherapy, 2025, 190, 118415. DOI: 10.1016/j.biopha.2025.118415

[28]Pluta W, Lubkowska A, Dudzińska W. Vascular endothelium in health and disease: Structure, function, assessment and role in metabolic disorders. Vascular Health and Risk Management, 2025, 21, 729-747. DOI: 10.2147/VHRM.S519426

[29]Loftus T, Benjamim J, Vaccarezza M, Stephan BC, Nguyen VH, Ashor A, et al. Stable isotope measurement of in vivo nitric oxide production in health and disease: An updated systematic review and meta-analysis. Nitric Oxide, 2026, 161, 18-26. DOI: 10.1016/j.niox.2026.01.001

[30]Alia S, Pedriali G, Compagnucci P, Valeri Y, Membrino V, Di Crescenzo T, et al. Mitochondria at the crossroads of cardiovascular disease: Mechanistic drivers and emerging therapeutic strategies. Cells, 2026, 15(4), 372. DOI: 10.3390/cells15040372

[31]Xie X, Yu T, Deng W, Xie S. Mitochondrial semi-autonomous inheritance in cardiovascular pathology: Emerging mechanisms and therapeutic opportunities. Pharmacological Research, 2026, 224, 108106. DOI: 10.1016/j.phrs.2026.108106

[32]Cochran JD, Walsh K. Clonal Hematopoiesis: The emergent CVD risk factor. Arteriosclerosis, Thrombosis, and Vascular, 2024, 44(4), 768-771. DOI: 10.1161/ATVBAHA.123.319562

[33]Jaiswal S, Libby P. Clonal haematopoiesis: Connecting ageing and inflammation in cardiovascular disease. Nature Reviews Cardiology, 2020, 17(3), 137-144. DOI: 10.1038/s41569-019-0247-5

[34]Lin AE, Bapat AC, Xiao L, Niroula A, Ye J, Wong WJ, et al. Clonal hematopoiesis of indeterminate potential with loss of Tet2 enhances risk for atrial fibrillation through Nlrp3 inflammasome activation. Circulation, 2024, 149(18), 1419-1434. DOI: 10.1161/CIRCULATIONAHA.123.065597

[35]Chen P, Li X. NLRP3 inflammasome in atherosclerosis: Mechanisms and targeted therapies. Frontiers in Pharmacology, 2024, 15, 1430236. DOI: 10.3389/fphar.2024.1430236

[36]Anastasiou IA, Kounatidis D, Vallianou NG, Rebelos E, Karampela I, Dalamaga M. Clonal hematopoiesis of indeterminate potential and cardiometabolic disease: Challenges, controversies and future perspectives. International Journal of Molecular Sciences, 2025, 27(1), 233. DOI: 10.3390/ijms27010233

[37]Oren O, Small AM, Lin AE, Libby P. Managing cardiovascular risk in clonal hematopoiesis of indeterminate potential: JACC: CardioOncology short-form primer. JACC CardioOncology, 2025, 7(5), 496-500. DOI: 10.1016/j.jaccao.2025.05.013

[38]Li Y, Li B, Chen WD, Wang YD. Role of G-protein coupled receptors in cardiovascular diseases. Frontiers in Cardiovascular Medicine, 2023, 10, 1130312. DOI: 10.3389/fcvm.2023.1130312

[39]Sun L, Ye RD. Role of G protein-coupled receptors in inflammation. Acta Pharmacologica Sinica, 2012, 33(3), 342-350. DOI: 10.1038/aps.2011.200

[40]Tanasescu MD, Rosu AM, Minca A, Rosu AL, Grigorie MM, Timofte D, et al. Metabolic dysfunction at the core: Revisiting the overlap of cardiovascular, renal, hepatic, and endocrine disorders. Life, 2026, 16(1), 172. DOI: 10.3390/life16010172

[41]Wang YH, Chen YS, Wang SY, Jin BY, Han XY, Hua CJ. Dysregulated cellular metabolism drives atherosclerotic plaque progression: A multi-cellular perspective. Frontiers in Cardiovascular Medicine, 2025, 12, 1562707. DOI: 10.3389/fcvm.2025.1562707

[42]Xie Y, Song Y, Shi S, Guo Y, Song W, Dou K. Glycaemic status modifies the association between cardiometabolic index and cardio-kidney outcomes: A multi-cohort analysis. Diabetes/Metabolism Research and Reviews, 2026, 42(1), e70124. DOI: 10.1002/dmrr.70124

[43]Vallon V, Verma S. Effects of SGLT2 inhibitors on kidney and cardiovascular function. Annual Review of Physiology, 2021, 83, 503-528. DOI: 10.1146/annurev-physiol-031620-095920

[44]Grejtakova D, Boronova I, Bernasovska J, Bellosta S. PCSK9 and lipid metabolism: Genetic variants, current therapies, and cardiovascular outcomes. Cardiovascular Drugs and Therapy, 2025, 39(6), 1439-1451. DOI: 10.1007/s10557-024-07599-5

[45]Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG, et al. MTHFR 677C-->T polymorphism and risk of coronary heart disease: A meta-analysis. JAMA, 2002, 288(16), 2023-2031. DOI: 10.1001/jama.288.16.2023

[46]Gupta SK, Kotwal J, Kotwal A, Dhall A, Garg S. Role of homocysteine & MTHFR C677T gene polymorphism as risk factors for coronary artery disease in young Indians. Indian Journal of Medical Research, 2012, 135(4), 506-512.

[47]Huang X, Qin X, Yang W, Liu L, Jiang C, Zhang X, et al. MTHFR gene and serum folate interaction on serum homocysteine lowering: Prospect for precision folic acid treatment. Arteriosclerosis Thrombosis and Vascular Biology, 2018, 38(3), 679-685. DOI: 10.1161/ATVBAHA.117.310211

[48]Qiu Y, Xu Q, Xie P, He C, Li Q, Yao X, et al. Epigenetic modifications and emerging therapeutic targets in cardiovascular aging and diseases. Pharmacological Research, 2025, 211, 107546. DOI: 10.1016/j.phrs.2024.107546

[49]Krekora J, Derwich M, Drożdż J, Pawlowska E, Blasiak J. Oxidative stress, mitochondrial quality control, autophagy, and sirtuins in heart failure. International Journal of Molecular Sciences, 2025, 26(19), 9826. DOI: 10.3390/ijms26199826

[50]Liu S, Liu J, Wang Y, Deng F, Deng Z. Oxidative stress: Signaling pathways, biological functions, and disease. MedComm, 2025, 6(7), e70268. DOI: 10.1002/mco2.70268

[51]Elbatarny M, Lu YT, Hu M, Coles J, Mital S, Ross-White A, et al. Systems biology approaches investigating mitochondrial dysfunction in cyanotic heart disease: A systematic review. EBioMedicine, 2025, 118, 105839. DOI: 10.1016/j.ebiom.2025.105839

[52]Luo Y, Zhang N, Yang J, Cui M, Tsoi KKF, Lip GYH, et al. AI-based multiomics profiling reveals complementary omics contributions to personalized prediction of cardiovascular disease. Nature Communications, 2026, 17(1), 2269. DOI: 10.1038/s41467-026-68956-6

[53]Reitz CJ, Kuzmanov U, Gramolini AO. Multi-omic analyses and network biology in cardiovascular disease. Proteomics, 2023, 23(21-22), e2200289. DOI: 10.1002/pmic.202200289

[54]Thorp EB, Karlstaedt A. Intersection of immunology and metabolism in myocardial disease. Circulation Research, 2024, 134(12), 1824-1840. DOI: 10.1161/CIRCRESAHA.124.323660

[55]Xiang A, Chang A, Zhou J, Jin J, Zhang X, Wang Q. Macrophage metabolism in inflammatory heart disease: New insights and therapeutic implications. Frontiers in Medicine, 2025, 12, 1664538. DOI: 10.3389/fmed.2025.1664538

[56]Chen R, Zhang H, Tang B, Luo Y, Yang Y, Zhong X, et al. Macrophages in cardiovascular diseases: Molecular mechanisms and therapeutic targets. Signal Transduction and Targeted Therapy, 2024, 9(1), 130. DOI: 10.1038/s41392-024-01840-1

[57]Li M, Sun X, Zeng L, Sun A, Ge J. Metabolic homeostasis of immune cells modulates cardiovascular diseases. Research, 2025, 8, 0679. DOI: 10.34133/research.0679

[58]Adachi Y, Grogan A, Kawakami R, Shiraki T, Sekimoto T, Tanaka T, et al. Recent advances in single-cell analysis of atherosclerotic plaque biology. JMA Journal, 2026, 9(1), 24-37. DOI: 10.31662/jmaj.2025-0397

[59]Single-cell RNA sequencing (scRNA-seq) and its insights into cellular heterogeneity in atherosclerosis. Vascular Pharmacology, 2025, 159, 107499. DOI: 10.1016/j.vph.2025.107499

[60]Boden KA, Chai J, Kufazvinei TTJ, Choudhury RP. Trained immunity and cardiovascular risk: An immunological perspective. Immunological Reviews, 2026, 337(1), e70095. DOI: 10.1111/imr.70095

[61]Liu Y, Zhang P, Kong W, Li J, Yang H, Bai H, et al. IRG1-itaconate axis in immunometabolism: Mechanistic roles and therapeutic potential in inflammatory diseases. Frontiers in Immunology, 2026, 17, 1767601. DOI: 10.3389/fimmu.2026.1767601

[62]Atallah R, Gindlhuber J, Heinemann A. Succinate in innate immunity: Linking metabolic reprogramming to immune modulation. Frontiers in Immunology, 2025, 16, 1661948. DOI: 10.3389/fimmu.2025.1661948

[63]Fanucchi S, Domínguez-Andrés J, Joosten LAB, Netea MG, Mhlanga MM. The intersection of epigenetics and metabolism in trained immunity. Immunity, 2021, 54(1), 32-43. DOI: 10.1016/j.immuni.2020.10.011

[64]Xu R, He X, Xu J, Yu G, Wu Y. Immunometabolism: Signaling pathways, homeostasis, and therapeutic targets. MedComm, 2024, 5(11), e789. DOI: 10.1002/mco2.789

[65]Potere N, Bonaventura A, Abbate A. Novel therapeutics and upcoming clinical trials targeting inflammation in cardiovascular diseases. Arteriosclerosis Thrombosis and Vascular Biology, 2024, 44(12), 2371-2395. DOI: 10.1161/ATVBAHA.124.319980

[66]Wong NR, Mohan J, Kopecky BJ, Guo S, Du L, Leid J, et al. Resident cardiac macrophages mediate adaptive myocardial remodeling. Immunity, 2021, 54(9), 2072-2088.e7. DOI: 10.1016/j.immuni.2021.07.003

[67]Kang M, Jia H, Feng M, Ren H, Gao J, Liu Y, et al. Cardiac macrophages in maintaining heart homeostasis and regulating ventricular remodeling of heart diseases. Frontiers in Immunology, 2024, 15, 1467089. DOI: 10.3389/fimmu.2024.1467089

[68]Guan F, Wang R, Yi Z, Luo P, Liu W, Xie Y, et al. Tissue macrophages: Origin, heterogenity, biological functions, diseases and therapeutic targets. Signal Transduction and Targeted Therapy, 2025, 10(1), 93. DOI: 10.1038/s41392-025-02124-y

[69]Shrestha S, Dick SA. Cardiac macrophages across space and time: Roles in homeostasis, disease, and remodeling. Canadian Journal of Cardiology, 2026, S0828-282X(26)00142-X. DOI: 10.1016/j.cjca.2026.02.025

[70]López-Méndez I, Uribe M, Juárez-Hernández E. Immunonutrition: Another player on the MASLD field. International Journal of Molecular Sciences, 2025, 26(18), 8928. DOI: 10.3390/ijms26188928

[71]Nessel I, Tsang VSK, Schroth J, Janssen H. Immunometabolism, an emerging field in perioperative and critical care medicine: A narrative review. British Journal of Anaesthesia, 2026, 136(4), 1202-1216. DOI: 10.1016/j.bja.2026.01.003

[72]Hajishengallis G, Chavakis T. Inflammageing and clonal haematopoiesis interplay and their impact on human disease. Nature Reviews Molecular Cell Biology, 2026, 10.1038/s41580-025-00936-y. DOI: 10.1038/s41580-025-00936-y

[73]Nadar S, Dohadwala TK, Kumaresan N, Ahamed SI, Fatima S. Clonal hematopoiesis at the crossroads of inflammaging and cardiovascular disease: Mechanistic insights and translational horizons. Clinical Hematology International, 2025, 7(4), 54-63. DOI: 10.46989/001c.146275

[74]Wong CK, McDonald A, Buttigieg MM, Rauh MJ. CHIP ahoy: Charting a decade of discovery in clonal hematopoiesis. Haematologica, 2026, 111(2), 457-469. DOI: 10.3324/haematol.2023.283896

[75]Ridker PM, Libby P, MacFadyen JG, Thuren T, Ballantyne C, Fonseca F, et al. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: Analyses from the canakinumab anti-inflammatory thrombosis outcomes study (CANTOS). European Heart Journal, 2018, 39(38), 3499-3507. DOI: 10.1093/eurheartj/ehy310

[76]Oren O, Libby P. Incorporating management of clonal hematopoiesis of indeterminate potential into cardiovascular practice. Circulation, 2025, 152(14), 975-977. DOI: 10.1161/CIRCULATIONAHA.125.075769

[77]Zanders L, Arifaj D, Wagner JUG, Dimmeler S. Cellular senescence, inflammaging and cardiovascular disease. Immunological Reviews, 2026, 337(1), e70084. DOI: 10.1111/imr.70084

[78]Xue S, Su Z, Liu D. Immunometabolism and immune response regulate macrophage function in atherosclerosis. Ageing Research Reviews, 2023, 90, 101993. DOI: 10.1016/j.arr.2023.101993

[79] Picos A, Seoane N, Campos-Toimil M, Viña D. Vascular senescence and aging: Mechanisms, clinical implications, and therapeutic prospects. Biogerontology, 2025, 26(3), 118. DOI: 10.1007/s10522-025-10256-5

[80]Fu Z, Yang S, Chang X, Liu P, Wang Y. Vascular smooth muscle cell metabolic reprogramming and phenotypic remodeling in atherosclerosis. Cell Death Discovery, 2025, 12(1), 64. DOI: 10.1038/s41420-025-02932-9

[81]Shi F, Dou J, Zhang X. Advancements in research to mitigate residual risk of atherosclerotic cardiovascular disease. European Journal of Medical Research, 2025, 30(1), 735. DOI: 10.1186/s40001-025-03006-3

[82]Li N, Pi C, Zhu S, Li X, Wang L, Shi P, et al. Opportunities for the treatment of atherosclerosis: Selectins. Pharmacological Research, 2025, 217, 107807. DOI: 10.1016/j.phrs.2025.107807

[83]Xiao Q, Hou R, Xie L, Niu M, Pan X, Zhu X. Macrophage metabolic reprogramming and atherosclerotic plaque microenvironment: Fostering each other? Clinical and Translational Medicine, 2023, 13(5), e1257. DOI: 10.1002/ctm2.1257

[84]Kim ME, Lee JS. Advances in the regulation of inflammatory mediators in nitric oxide synthase: Implications for disease modulation and therapeutic approaches. International Journal of Molecular Sciences, 2025, 26(3), 1204. DOI: 10.3390/ijms26031204

[85]Zhili G, Zhimin G, Nenghua Z. Role of vascular endothelial dysfunction and metabolic eprogramming of immune cells in the development and ogression of atherosclerosis. Frontiers in Physiology, 2025, 16, 1624225. DOI: 10.3389/fphys.2025.1624225

[86]Gao C, Wang Y. YAP: The nexus between metabolism and cardiac remodeling. Journal of Clinical Investigation, 2022, 132(6), e157664. DOI: 10.1172/JCI157664

[87]Kopecky BJ, Lavine KJ. Cardiac macrophage metabolism in health and disease. Trends in Endocrinology and Metabolism, 2024, 35(3), 249-262. DOI: 10.1016/j.tem.2023.10.011

[88]Cai G, Zhang X, Jiao J, Du W, Yan M. Targeting the cGAS-STING pathway to modulate immune inflammation in diabetes and cardiovascular complications: Mechanisms and therapeutic insights. Current Issues in Molecular Biology, 2025, 47(9), 750. DOI: 10.3390/cimb47090750

[89]Szabo M, Lagos D, Cross E, Collier J, Horvath R. Mitochondrial DNA release and inflammation in mitochondrial disease pathogenesis. Brain, 2026, awag037. DOI: 10.1093/brain/awag037

[90]Mou J, Chen Y, Zhu X, Xu B, Wang M, Xie J, et al. Emerging role of the cGAS-STING pathway in cardiovascular diseases: Biologic function, mechanisms and targeted therapy. Molecular Medicine, 2025, 31(1), 218. DOI: 10.1186/s10020-025-01273-8

[91]Yue T, Zheng D, He J, Xiong S, Xu J, Hou J. Mitochondrial dysfunction as a therapeutic nexus in HFpEF: Therapeutic target and pharmacological advances. Frontiers in Pharmacology, 2025, 16, 1676988. DOI: 10.3389/fphar.2025.1676988

[92]Kumar V, Yepuri G, Kumar G, Schmidt AM. Editorial: Cardiovascular immunometabolism-a complex interplay between the immune system and metabolism in the heart. Frontiers in Endocrinology, 2025, 16, 1613774. DOI: 10.3389/fendo.2025.1613774

[93]Shu B, Chen X, Liu Z, Tang H, Yang B, Fu C. Pleiotropic effects of SGLT2 inhibitors: A focus on macrophage-mediated action. Pharmacological Research, 2025, 222, 108046. DOI: 10.1016/j.phrs.2025.108046

[94]Ma T, Wang L, Yan X, Li F. Targeted Anti-inflammatory therapy in cardiovascular events: Challenges and opportunities. Journal of Clinical Hypertension, 2025, 27(11), e70172. DOI: 10.1111/jch.70172

[95]Shah SR, Abbasi Z, Fatima M, Ochani RK, Shahnawaz W, Asim Khan M, et al. Canakinumab and cardiovascular outcomes: Results of the CANTOS trial. Journal of Community Hospital Internal Medicine Perspectives, 2018, 8(1), 21-22. DOI: 10.1080/20009666.2018.1428023

[96]Khinchin J, Rakoubian A, Romano V, Ryan T, Yarbro J, Kobayashi S, et al. Repurposing metformin for cardioprotection: Mechanisms and therapeutic potential across cardiovascular pathologies. Frontiers in Pharmacology, 2026, 17, 1681783. DOI: 10.3389/fphar.2026.1681783

[97]Kret Z, Akinola OM, Ahlidja W, Joe B. Food as medicine for hypertension: Microbiota as mediators. Hypertension, 2025, 82(10), 1569-1589. DOI: 10.1161/HYPERTENSIONAHA.125.17950

[98]Pisaniello AD, Psaltis PJ, King PM, Liu G, Gibson RA, Tan JT, et al. Omega-3 fatty acids ameliorate vascular inflammation: A rationale for their atheroprotective effects. Atherosclerosis, 2021, 324, 27-37. DOI: 10.1016/j.atherosclerosis.2021.03.003

[99]Sheng Z, Luo Q, Liu X, Yang X. Bioactives and exercise synergize to modulate AMPK and inflammation. Frontiers in Immunology, 2026, 16, 1670379. DOI: 10.3389/fimmu.2025.1670379

[100]Wang X, Chen L, Wei J, Zheng H, Zhou N, Xu X, et al. The immune system in cardiovascular diseases: From basic mechanisms to therapeutic implications. Signal Transduction and Targeted Therapy, 2025, 10(1), 166. DOI: 10.1038/s41392-025-02220-z

[101]Rong W, Zhou Y. Decoding cardiac metabolic reprogramming through single-cell multi-omics: From mechanisms to therapeutic applications. Frontiers in Cell and Developmental Biology, 2025, 13, 1710474. DOI: 10.3389/fcell.2025.1710474

[102]Li K, Samiei S, Pikulska D, Foecking S, Kuppe C. Advancing cardiovascular research with single-cell and spatial transcriptomics. Circulation Research, 2026, 138(1), e325795. DOI: 10.1161/CIRCRESAHA.125.325795

[103]Barcia Durán JG, Das D, Gildea M, Amadori L, Gourvest M, Kaur R, et al. Immune checkpoint landscape of human atherosclerosis and influence of cardiometabolic factors. Nature Cardiovascular Research, 2024, 3(12), 1482-1502. DOI: 10.1038/s44161-024-00563-4

[104]Lancellotti P, Oury C. Recent advances in cardiovascular medicine: From molecular mechanisms to precision care. Acta Cardiologica, 2025, 80(9), 949-953. DOI: 10.1080/00015385.2025.2579430

[105]Spray L, Richardson G, Haendeler J, Altschmied J, Rumampouw V, Wallis SB, et al. Cardiovascular inflammaging: Mechanisms, consequences, and therapeutic perspectives. Cell Reports Medicine, 2025, 6(9), 102264. DOI: 10.1016/j.xcrm.2025.102264

[106]Lopaschuk GD, Karwi QG, Tian R, Wende AR, Abel ED. Cardiac energy metabolism in heart failure. Circulation Research, 2021, 128(10), 1487-1513. DOI: 10.1161/CIRCRESAHA.121.318241

[107]Chen B, Guo J, Ye H, Wang X, Feng Y. Role and molecular mechanisms of SGLT2 inhibitors in pathological cardiac remodeling (Review). Molecular Medicine Reports, 2024, 29(5), 73. DOI: 10.3892/mmr.2024.13197

[108]Bodea OM, Serban S, Craciun ML, Mateescu DM, Florescu E, Muresan CO, et al. Effects of SGLT2 inhibitors on clinical outcomes, symptoms, functional capacity, and cardiac remodeling in heart failure: A comprehensive systematic review and multidomain meta-analysis of randomized trials. Journal of Clinical Medicine, 2026, 15(1), 378. DOI: 10.3390/jcm15010378

[109]Svanström H, Mkoma GF, Hviid A, Pasternak B. SGLT-2 inhibitors and mortality among patients with heart failure with reduced ejection fraction: Linked database study. BMJ, 2024, 387, e080925. DOI: 10.1136/bmj-2024-080925

[110]Barbieri L, Tumminello G, Fichtner I, Corsini A, Santos RD, Carugo S, et al. PCSK9 and coronary artery plaque-new opportunity or red herring? Current Atherosclerosis Reports, 2024, 26(10), 589-602. DOI: 10.1007/s11883-024-01230-6

[111]Tavori H, Giunzioni I, Fazio S. PCSK9 inhibition to reduce cardiovascular disease risk: Recent findings from the biology of PCSK9. Current Opinion in Endocrinology Diabetes and Obesity, 2015, 22(2), 126-132. DOI: 10.1097/MED.0000000000000137

[112]Jiang Y, Wang Y, Ma S, Qian L, Jing Y, Chen X, et al. Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein cholesterol in hyperlipidemia patients: A systematic network meta-analysis. Frontiers in Cardiovascular Medicine, 2025, 11, 1415668. DOI: 10.3389/fcvm.2024.1415668

[113]Priyanka F, Durga F, Affan M, Venjhraj F. The PCSK9 inhibitors: A lipid-lowering therapy to treat atherosclerotic cardiovascular diseases. Nature Cell and Science, 2025, 3(2), 92-99. DOI: 10.61474/ncs.2024.00056

[114]Chaudhary D, Guleria D, Aggarwal H, Mishra V, Chauhan A, Dufossé L, et al. Nutrigenomics and personalized diets-Tailoring nutrition for optimal health. Applied Food Research, 2025, 5(1), 100980. DOI: 10.1016/j.afres.2025.100980

[115]Mundt C, Yusufoğlu B, Kudenko D, Mertoğlu K, Esatbeyoglu T. AI-driven personalized nutrition: Integrating omics, ethics, and digital health. Molecular Nutrition & Food Research, 2025, 69(24), e70293. DOI: 10.1002/mnfr.70293

[116]Debri RP, De Lorenzo A, Conte R, Peluso G. Functional foods as vehicles for bioactive compounds: Chemical and nutritional perspectives on health and disease prevention. International Journal of Molecular Sciences, 2026, 27(5), 2293. DOI: 10.3390/ijms27052293

[117]Balamurugan J, Adeyeye SAO. Artificial intelligence in nutrigenomics: A critical review on functional food insights and personalized nutrition pathways. Journal of Human Nutrition and Dietetics, 2026, 39(1), e70200. DOI: 10.1111/jhn.70200

[118]Saeidifard F, Medina-Inojosa JR, West CP, Olson TP, Somers VK, Bonikowske AR, et al. The association of resistance training with mortality: A systematic review and meta-analysis. European Journal of Preventive Cardiology, 2019, 26(15), 1647-1665. DOI: 10.1177/2047487319850718

[119]Clark A, Mach N. The crosstalk between the gut microbiota and mitochondria during exercise. Frontiers in Physiology, 2017, 8, 319. DOI: 10.3389/fphys.2017.00319

[120]Paluch AE, Boyer WR, Franklin BA, Laddu D, Lobelo F, Lee DC, et al. Resistance exercise training in individuals with and without cardiovascular disease: 2023 update: A scientific statement from the American Heart Association. Circulation, 2024, 149(3), e217-e231. DOI: 10.1161/CIR.0000000000001189

[121]Shero JA, Lindholm ME, Sandri M, Stanford KI. Skeletal muscle as a mediator of interorgan crosstalk during exercise: Implications for aging and obesity. Circulation Research, 2025, 136(11), 1407-1432. DOI: 10.1161/CIRCRESAHA.124.325614

[122]Conversano C, Orrù G, Pozza A, Miccoli M, Ciacchini R, Marchi L, et al. Is mindfulness-based stress reduction effective for people with hypertension? A systematic review and meta-analysis of 30 years of evidence. International Journal of Environmental Research and Public Health, 2021, 18(6), 2882. DOI: 10.3390/ijerph18062882

[123]Kumar M, Yan P, Kuchel GA, Xu M. Cellular senescence as a targetable risk factor for cardiovascular diseases: Therapeutic implications: JACC family series. JACC Basic to Translational Science, 2024, 9(4), 522-534. DOI: 10.1016/j.jacbts.2023.12.003

[124]Fang YP, Zhao Y, Huang JY, Yang X, Liu Y, Zhang XL. The functional role of cellular senescence during vascular calcification in chronic kidney disease. Frontiers in Endocrinology, 2024, 15, 1330942. DOI: 10.3389/fendo.2024.1330942

[125]Atlante S, Gottardi Zamperla M, Cis L, Farsetti A, Gaetano C. Senolytic therapies for cardiovascular aging: Tackling fibrosis and metabolic dysfunction. European Journal of Internal Medicine, 2025, 140, 106413. DOI: 10.1016/j.ejim.2025.07.009

[126]Bian X, Snow ZK, Zinn CJ, Bratulin AL, Elhusseiny KM, Tchkonia T, et al. Senolytics, dasatanib plus quercetin, reduce kidney inflammation, senescent cell abundance, and injury while restoring geroprotective factors in murine diabetic kidney disease. EBioMedicine, 2026, 124, 106124. DOI: 10.1016/j.ebiom.2026.106124

[127]Thompson PL, Nidorf SM. Anti-inflammatory therapy with canakinumab for atherosclerotic disease: Lessons from the CANTOS trial. Journal of Thoracic Disease, 2018, 10(2), 695-698. DOI: 10.21037/jtd.2018.01.119

[128]Viana-Huete V, Fuster JJ. Potential therapeutic value of interleukin 1b-targeted strategies in atherosclerotic cardiovascular disease. Revista Española De Cardiología (English Edition), 2019, 72(9), 760-766. DOI: 10.1016/j.rec.2019.03.006

[129]Yesilyurt-Dirican ZE, Qi C, Wang YC, Simm A, Deelen L, Hafiz Abbas Gasim A, et al. SGLT2 inhibitors as a novel senotherapeutic approach. NPJ Aging, 2025, 11(1), 35. DOI: 10.1038/s41514-025-00227-y

[130]Mansfield L, Ramponi V, Gupta K, Stevenson T, Mathew AB, Barinda AJ, et al. Emerging insights in senescence: Pathways from preclinical models to therapeutic innovations. NPJ Aging, 2024, 10(1), 53. DOI: 10.1038/s41514-024-00181-1

[131]Antonioli L, Fornai M, Pellegrini C, Pacher P, Haskó G. Adenosine signaling as target in cardiovascular pharmacology. Current Opinion in Pharmacology, 2023, 71, 102393. DOI: 10.1016/j.coph.2023.102393

[132]Qian Y, Dong S, Nie M, Tian Y, Liu M, Liu X, et al. Delayed administration of an angiotensin II type 2 receptor agonist promotes functional recovery of the brain and heart after traumatic brain injury. Journal of Neurotrauma, 2024, 41(5-6), 660-670. DOI: 10.1089/neu.2023.0375

[133]Singh DD, Yadav DK, Shin D. Next-generation antioxidants in cardiovascular disease: Mechanistic insights and emerging therapeutic strategies. Antioxidants, 2026, 15(2), 164. DOI: 10.3390/antiox15020164

[134]Liu B, Chen L, Gao M, Dai M, Zheng Y, Qu L, et al. A comparative study of the efficiency of mitochondria-targeted antioxidants MitoTEMPO and SKQ1 under oxidative stress. Free Radical Biology and Medicine, 2024, 224, 117-129. DOI: 10.1016/j.freeradbiomed.2024.08.022

[135]Fonseka O, Gare SR, Chen X, Zhang J, Alatawi NH, Ross C, et al. Molecular mechanisms underlying heart failure and their therapeutic potential. Cells, 2025, 14(5), 324. DOI: 10.3390/cells14050324

[136]Zielonka J, Joseph J, Sikora A, Hardy M, Ouari O, Vasquez-Vivar J, et al. Mitochondria-targeted triphenylphosphonium-based compounds: Syntheses, mechanisms of action, and therapeutic and diagnostic applications. Chemical Reviews, 2017, 117(15), 10043-10120. DOI: 10.1021/acs.chemrev.7b00042

[137]Tung C, Varzideh F, Farroni E, Mone P, Kansakar U, Jankauskas SS, et al. Elamipretide: A review of its structure, mechanism of action, and therapeutic potential. International Journal of Molecular Sciences, 2025, 26(3), 944. DOI: 10.3390/ijms26030944

[138]Mentzer RM Jr, Bartels C, Bolli R, Boyce S, Buckberg GD, Chaitman B, et al. Sodium-hydrogen exchange inhibition by cariporide to reduce the risk of ischemic cardiac events in patients undergoing coronary artery bypass grafting: Results of the EXPEDITION study. The Annals of Thoracic Surgery, 2008, 85(4), 1261-1270. DOI: 10.1016/j.athoracsur.2007.10.054

[139]Mitchell W, Pharaoh G, Tyshkovskiy A, Campbell M, Marcinek DJ, Gladyshev VN. The mitochondria-targeted peptide therapeutic elamipretide improves cardiac and skeletal muscle function during aging without detectable changes in tissue epigenetic or transcriptomic age. Aging Cell, 2025, 24(6), e70026. DOI: 10.1111/acel.70026

[140]Ball M, van Bergen NJ, Compton AG, Thorburn DR, Rahman S, Christodoulou J. Therapies for mitochondrial disease: Past, present, and future. Journal of Inherited Metabolic Disease, 2025, 48(4), e70065. DOI: 10.1002/jimd.70065

[141]Nahar N, Sohag MSU. Advancements in mitochondrial-targeted antioxidants: Organelle-specific drug delivery for disease management. Advances in Redox Research, 2025, 100142. DOI: 10.1016/j.arres.2025.100142

[142]Fatehi Hassanabad A, Zarzycki AN, Patel VB, Fedak PWM. Current concepts in the epigenetic regulation of cardiac fibrosis. Cardiovascular Pathology, 2024, 73, 107673. DOI: 10.1016/j.carpath.2024.107673

[143]Yan H, Yin Y, Zhou Y, Li Z, Li Y, Ren L, et al. Regulation of cardiovascular diseases by histone deacetylases and NADPH oxidases. Redox Biology, 2024, 77, 103379. DOI: 10.1016/j.redox.2024.103379

[144]Desroche LM, Trimaille A, Garban T, Bouleti C. Artificial intelligence in cardiovascular medicine: An exoskeleton for perception, reasoning and action. Archives of Cardiovascular Diseases, 2025, 118(11), 613-620. DOI: 10.1016/j.acvd.2025.07.012

[145]Khoshfekr Rudsari H, Tseng B, Zhu H, Song L, Gu C, Roy A, et al. Digital twins in healthcare: A comprehensive review and future directions. Frontiers in Digital Health, 2025, 7, 1633539. DOI: 10.3389/fdgth.2025.1633539

[146]Mirzoyev U, Mirzoyev K. Digital medicine in the management of heart failure: From reactive care to predictive, pathophysiology-driven strategies. Healthcare, 2026, 14(4), 455. DOI: 10.3390/healthcare14040455

[147]Gaoudam N, Sakhamudi SK, Kamal B, Addla N, Reddy EP, Ambala M, et al. Wearable devices and ai-driven remote monitoring in cardiovascular medicine: A narrative review. Cureus, 2025, 17(8), e90208. DOI: 10.7759/cureus.90208

[148]Lin M, Guo J, Gu Z, Tang W, Tao H, You S, et al. Machine learning and multi-omics integration: Advancing cardiovascular translational research and clinical practice. Journal of Translational Medicine, 2025, 23(1), 388. DOI: 10.1186/s12967-025-06425-2

[149]Cunningham JW, Abraham WT, Bhatt AS, Dunn J, Felker GM, Jain SS, et al. Artificial intelligence in cardiovascular clinical trials. Journal of the American College of Cardiology, 2024, 84(20), 2051-2062. DOI: 10.1016/j.jacc.2024.08.069

[150]Xu Q, Li Y, Zhu M, Cai Y, Cheng X, Wang W, et al. Precision cardiovascular medicine with big data and AI. npj Digital Medicine, 2026. DOI: 10.1038/s41746-026-02538-0

[151]Marei I, Abu Samaan T, Al-Quradaghi MA, Farah AA, Mahmud SH, Ding H, et al. 3D tissue-engineered vascular drug screening platforms: Promise and considerations. Frontiers in Cardiovascular Medicine, 2022, 9, 847554. DOI: 10.3389/fcvm.2022.847554

[152]Shen D, Wang Y, Zhou X, Xu Z, Zhou J, Balasubramanian V, et al. The application of 3d printing in cardiac patch manufacture. Advanced Healthcare Materials, 2026, e04250. DOI: 10.1002/adhm.202504250

[153]Osório TG, Pavesi E, El-Ardat KA, Qureshi N, Cassidy L, St John TL, et al. Single-cell multi-omics for precision cardiovascular and longevity medicine: From methods to clinical translation. Frontiers in Aging, 2025, 6, 1656727. DOI: 10.3389/fragi.2025.1656727

[154]Costa F, Gomez Doblas JJ, Díaz Expósito A, Adamo M, D'Ascenzo F, Kołtowski L, et al. Artificial intelligence in cardiovascular pharmacotherapy: Applications and perspectives. European Heart Journal, 2025, 46(37), 3616-3627. DOI: 10.1093/eurheartj/ehaf474

[155]Kolk MZH, Ruipérez-Campillo S, Wilde AAM, Knops RE, Narayan SM, Tjong FVY. Prediction of sudden cardiac death using artificial intelligence: Current status and future directions. Heart Rhythm, 2025, 22(3), 756-766. DOI: 10.1016/j.hrthm.2024.09.003

[156]Magouliotis DE, Sicouri N, Ramlawi L, Baudo M, Androutsopoulou V, Sicouri S. Artificial intelligence in adult cardiovascular medicine and surgery: Real-world deployments and outcomes. Journal of Personalized Medicine, 2026, 16(2), 69. DOI: 10.3390/jpm16020069

[157]Bartusik-Aebisher D, Podgórski R, Serafin I, Aebisher D. Targeted and biomimetic nanoparticles for atherosclerosis therapy: A review of emerging strategies. Biomedicines, 2025, 13(7), 1720. DOI: 10.3390/biomedicines13071720

[158]Jha G, Sharma RB, Sridhar S, Hayagreev D, Sinha T, Kaur H, et al. Nanoparticle-based therapies for cardiovascular diseases: A literature review of recent advances and clinical potential. Cureus, 2024, 16(10), e72808. DOI: 10.7759/cureus.72808

[159]Ćurčić M, Hadžić B, Gilić M, Lazarević Z, Ilić A. BaTiO3 nanocarriers: Advancing targeted therapies with smart drug release. Pharmaceutics, 2025, 17(9), 1203. DOI: 10.3390/pharmaceutics17091203

[160]Desai N, Rana D, Patel M, Bajwa N, Prasad R, Vora LK. Nanoparticle therapeutics in clinical perspective: Classification, marketed products, and regulatory landscape. Small, 2025, 21(29), e2502315. DOI: 10.1002/smll.202502315

[161]Vo QD, Saito Y, Nakamura K, Iida T, Yuasa S. Induced pluripotent stem cell-derived cardiomyocytes therapy for ischemic heart disease in animal model: A meta-analysis. International Journal of Molecular Sciences, 2024, 25(2), 987. DOI: 10.3390/ijms25020987

[162]Kim WJ, Yoon JW, Sim WS, Kim YS, Chae S, Choi B, et al. Bioprinting of cardiac patches with gold-nanowires and tri-culture system for the treatment of myocardial infarction. Chemical Engineering Journal, 2025, 171562. DOI: 10.1016/j.cej.2025.171562

[163]Dashti M, Mohammaddust Sarab M, Shad F, Dehnavi S. CRISPR-mediated engineering of mesenchymal stromal/stem cells: A summary of recent progress in immunological applications for regenerative medicine and cancer therapy. Stem Cell Research & Therapy, 2025, 16(1), 592. DOI: 10.1186/s13287-025-04723-6

[164]Rayat Pisheh H, Sani M. Mesenchymal stem cells derived exosomes: A new era in cardiac regeneration. Stem Cell Research & Therapy, 2025, 16(1), 16. DOI: 10.1186/s13287-024-04123-2

[165]Jebran AF, Seidler T, Tiburcy M, Daskalaki M, Kutschka I, Fujita B, et al. Engineered heart muscle allografts for heart repair in primates and humans. Nature, 2025, 639(8054), 503-511. DOI: 10.1038/s41586-024-08463-0

[166]Leon-Mimila P, Wang J, Huertas-Vazquez A. Relevance of multi-omics studies in cardiovascular diseases. Frontiers in Cardiovascular Medicine, 2019, 6, 91. DOI: 10.3389/fcvm.2019.00091

[167]Joshi A, Rienks M, Theofilatos K, Mayr M. Systems biology in cardiovascular disease: A multiomics approach. Nature Reviews Cardiology, 2021, 18(5), 313-330. DOI: 10.1038/s41569-020-00477-1

[168]de Ruiter SC, van Vugt M, Finan C, Grobbee DE, de Kleijn DPV, Pasterkamp G, et al. Integrating multi-modal omics to identify therapeutic atherosclerosis pathways for coronary heart disease. EBioMedicine, 2025, 121, 105966. DOI: 10.1016/j.ebiom.2025.105966

[169]Ritchie SC, Jiang X, Pennells L, Xu Y, Coffey C, Liu Y, et al. Combined clinical, metabolomic, and polygenic scores for cardiovascular risk prediction. European Heart Journal, 2025, ehaf947. DOI: 10.1093/eurheartj/ehaf947

[170]Mocumbi AO. Cardiovascular health care in low- and middle-income countries. Circulation, 2024, 149(8), 557-559. DOI: 10.1161/CIRCULATIONAHA.123.065717

[171]Soni A, Karna S, Patel H, Fahey N, Raithatha S, Handorf A, et al. Study protocol for smartphone monitoring for atrial fibrillation in real-time in India (SMART-India): A community-based screening and referral programme. BMJ Open, 2017, 7(12), e017668. DOI: 10.1136/bmjopen-2017-017668

[172]Tolu-Akinnawo O, Ezekwueme F, Awoyemi T. Telemedicine in cardiology: Enhancing access to care and improving patient outcomes. Cureus, 2024, 16(6), e62852. DOI: 10.7759/cureus.62852

[173]Hon JJ, Carr-White G. The digital divide in cardiovascular care: Who gets left behind? European Heart Journal-Digital Health, 2026, 7(2), ztag011. DOI: 10.1093/ehjdh/ztag011

[174]Sharma PK, Chen CY. AI-integrated micro/nanorobots for biomedical applications: Recent advances in design, fabrication, and functions. Biosensors, 2025, 15(12), 793. DOI: 10.3390/bios15120793

Downloads

Published

2026-04-21

Issue

Vol. 1 No. 1 (2026)

Section

Articles

License

Copyright (c) 2026 Uzma Manzoor, Omneya Abdelkarem, Azraida Hajar (Author)

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

Manzoor, U., Abdelkarem, O. ., & Hajar, A. . (2026). The Immunometabolic Architecture of Cardiovascular Disease: From Molecular Mechanisms to Precision Therapeutic Strategies. Cardiovascular Disease Prevention and Control, 1(1), 39-60. https://doi.org/10.64229/z36aqk64